Progyny, Inc.

Progyny, Inc. (PGNY) Market Cap

Progyny, Inc. has a market capitalization of $1.48B.

Financials based on reported quarter end 2025-12-31

Price: $18.12

0.19 (1.06%)

Market Cap: 1.48B

NASDAQ · time unavailable

CEO: David J. Schlanger

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2019-10-25

Website: https://www.progyny.com

Progyny, Inc. (PGNY) - Company Information

Market Cap: 1.48B · Sector: Healthcare

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Analyst Sentiment

80%
Strong Buy

Based on 11 ratings

Analyst 1Y Forecast: $30.33

Average target (based on 2 sources)

Consensus Price Target

Low

$28

Median

$30

High

$35

Average

$31

Potential Upside: 70.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PROGYNY INC (PGNY) — Investment Overview

🧩 Business Model Overview

Progyny Inc. (NASDAQ: PGNY) is a leading fertility benefits management company, offering comprehensive solutions for family building and reproductive health to employers across the United States. The company partners with employers to design, implement, and manage fertility and family building benefit programs for their employees. Progyny’s model integrates benefit plan design, a curated provider network, robust data analytics, member support, and pharmacy benefits management into a single, streamlined platform, aiming to improve clinical outcomes, reduce costs, and enhance the employee experience. Progyny's focus on optimizing the patient journey, employer flexibility, and clinical results has differentiated its approach within the broader healthcare benefits industry.

💰 Revenue Streams & Monetisation Model

Progyny generates revenue largely through contractual agreements with self-insured employers. Its main revenue streams include: - **Fertility Benefit Services:** Employers contract with Progyny to provide a suite of fertility services—such as in vitro fertilization (IVF), egg freezing, intrauterine insemination (IUI), genetic testing, and other assisted reproductive technologies. Revenue is recognized based on client contract terms, typically as services are rendered. - **Pharmacy Benefit Services:** Progyny also provides specialized pharmacy benefit management, covering fertility-specific medications through partnerships with specialty pharmacies. The company earns revenue from dispensing prescriptions required throughout members’ fertility treatment journeys. - **Administrative Fees:** A smaller share of revenue comes from fees associated with managing the benefit plans, including care advocacy, provider network access, and utilization management. This multi-faceted model allows Progyny to capture value from both the service and pharmaceutical aspects of fertility treatment, reinforcing its role as a holistic partner for employers and employees.

🧠 Competitive Advantages & Market Positioning

Progyny’s strategic positioning is supported by several durable competitive advantages: - **Integrated Platform:** By combining benefit design, best-in-class provider networks, concierge member support, and pharmacy services, Progyny delivers a seamless end-to-end experience for its clients and their employees. - **Proprietary Provider Network:** The company has cultivated a curated network of top fertility specialists and clinics, ensuring high-quality care and greater consistency in outcomes. - **Data & Analytics Capabilities:** Progyny leverages robust data analytics to optimize treatment plans, track success rates, manage costs, and educate employer clients on plan performance. - **Brand & Trust:** Progyny is recognized as a leader in fertility benefits, with a strong employer client base that includes many Fortune 500 companies and large organizations across diverse industries. - **Member-Centric Advocacy:** The company’s model emphasizes tailored support for each member, driving high satisfaction levels and better decision-making throughout the fertility journey. Relative to traditional health insurers and generalist benefits administrators, Progyny’s specialized offering and differentiated outcomes position it as the “go-to” solution for employers seeking to address the growing demand for family building benefits.

🚀 Multi-Year Growth Drivers

Progyny is well-positioned to benefit from long-term secular trends and multiple growth avenues: - **Expansion of Employer-Sponsored Fertility Benefits:** Driven by increased awareness, demand among younger workforces, DEI (Diversity, Equity, Inclusion) initiatives, and competitive talent environments, more employers are offering fertility and family building benefits each year. - **Growing Market Penetration:** Progyny continues to broaden its reach into new industry verticals, regional markets, and employer sizes—including mid-sized businesses, which have traditionally been underserved. - **Increasing Utilization and Attach Rates:** As stigma declines and benefits become better understood, utilization rates among covered employees are rising. Progyny also has opportunities to “attach” additional services, such as surrogacy, adoption, and broader women’s health benefits. - **Pharmacy Benefit Services Expansion:** The increased complexity and cost of fertility medications provide continued opportunity for growth in Progyny's pharmacy-related revenues. - **Innovation and Service Line Extensions:** The company can further develop digital engagement tools, integrate adjacent health services (menopause, genetic testing, male fertility), and form strategic partnerships to enhance its platform. Together, these drivers create a favorable backdrop for sustained membership and revenue growth beyond the near term.

⚠ Risk Factors to Monitor

While Progyny operates in an attractive niche, investors should remain aware of several material risks: - **Regulatory Landscape:** Changes in health insurance, employment, or pharmaceutical regulation could impact coverage mandates or reimbursement levels for fertility care. - **Concentration Risk:** A significant portion of revenue may be derived from a limited number of large employer clients, increasing exposure to contract renewals and competitive pricing pressures. - **Competitive Dynamics:** Larger health insurers, benefits administrators, or emerging startups could intensify competition, leading to margin compression or lost market share. - **Economic Sensitivity:** Employer willingness to offer or renew fertility benefits could wane during economic downturns, while employee utilization may fluctuate with macroeconomic conditions. - **Cost Management:** Escalating drug costs or clinical expenses could pressure margins if not sufficiently passed through to clients or offset by efficiencies. Vigilance around these potential headwinds is essential in assessing the long-term risk-reward balance.

📊 Valuation & Market View

Progyny is typically valued as a high-growth healthcare services company, with premiums attributed to its strong revenue visibility, recurring business model, and secular industry tailwinds. Key metrics include revenue multiples (EV/Sales), gross margin sustainability, and client retention rates. Investors generally expect Progyny to deliver continued top-line growth, driven by new client wins, expanded service offerings, and consistently high member satisfaction. Margin expansion is also a focal point, particularly as operating leverage improves with scale. Relative to broader managed care and benefit administration peers, Progyny commands higher valuation multiples, reflecting its focused specialization, differentiation, and significant runway within an underpenetrated and rapidly growing benefits category.

🔍 Investment Takeaway

Progyny represents a unique investment proposition at the intersection of healthcare, technology, and workplace benefits. Its mission-driven approach, integrated business model, and strong brand equity support durable leadership in the fast-growing fertility benefits space. A supportive regulatory backdrop, broadening client demand, and continuous service innovation provide multiple long-term levers for growth. However, the company’s success hinges on its ability to sustain competitive advantages, manage healthcare cost inflation, and navigate the evolving employer benefits landscape. For investors seeking exposure to the secular adoption of reproductive health benefits by U.S. employers, Progyny is a high-potential pure play with strong embedded growth characteristics, but not without execution and industry risks that warrant careful monitoring.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"PGNY reported revenue of $318.4M and a net income of $12.5M, resulting in an EPS of $0.15 for the most recent quarter. The company demonstrates a solid operating cash flow of $54.2M and a robust free cash flow of $48.6M. With total assets of $742.4M against total liabilities of $226.4M, PGNY maintains a healthy balance sheet with a net debt position showing positive equity of $516.0M. However, the company's stock has experienced substantial declines, including a 1-year price change of -18.14% and a year-to-date loss of nearly 30%. The current market price stands at $18.05, significantly below the consensus price target of $30.8. Despite the profitability illustrated in its financial performance, the negative market trends may affect investor confidence and sentiment going forward."

Revenue Growth

Neutral

Positive growth in revenue indicating market acceptance.

Profitability

Fair

Profitable with positive net income, but still modest performance.

Cash Flow Quality

Positive

Strong operating and free cash flow reflecting solid operational efficiency.

Leverage & Balance Sheet

Good

Healthy balance sheet with no net debt; strong equity position.

Shareholder Returns

Neutral

Negative price performance over the year with no dividends paid.

Analyst Sentiment & Valuation

Caution

Market sentiment is currently bearish, impacting stock valuation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Progyny delivered a strong Q4 close and momentum into 2026, with FY2025 revenue of $1.29B and adjusted EBITDA of $222M (both double-digit growth and above guidance midpoint by $90M/$28M). Q4 revenue also beat expectations, exceeding the top end of its guidance range by nearly $11M as member engagement/utilization ran ahead of assumptions. The key moving part for 2026 is not the economic engine (utilization/cost containment remains stable) but the covered-lives outlook: 7.2M lives guided, down due to ~400k administrative changes to existing clients—management reiterated that guidance is utilization-driven rather than population-driven. Profitability shows operating leverage: nearly 200 bps gross margin expansion in 2025 and modest adjusted EBITDA margin gains despite platform investment. Capital flexibility remains high (no debt; ~$310M cash/marketable securities) while buybacks continue (>3.3M shares for ~$84M in Q4). Risks center on potential ART variability, Rx regulatory/fee-structure evolution, and Select’s predictability as it scales (financial contribution expected starting 2027).

AI IconGrowth Catalysts

  • Near 100% client retention (including all largest employers) supporting 2026 revenue stability
  • 30% of client base expanding benefits for 2026 via upsells/service enhancements
  • More than 2.7 million members to gain access to pregnancy/postpartum/menopause newest services in 2026
  • Clinical outcomes/cost containment improvements: elimination of unnecessary treatments, reduced high-risk pregnancies, fewer NICU events

Business Development

  • Progyny Select go-to-market via brokers and other third-party distribution partners (Select sold for employers 1,000+ lives; program structured with guardrails including no individual member opt-outs)
  • Network clinic partnership model remains core to clinical quality and outcomes delivery

AI IconFinancial Highlights

  • FY2025: Revenue $1.29B and adjusted EBITDA $222M; both double-digit vs 2024; above original guidance midpoint by $90M (revenue) and $28M (adj EBITDA)
  • Q4 performance: revenue exceeded the top end of the guidance range by nearly $11M (driven by stronger member utilization/engagement pace vs assumptions)
  • Revenue growth: Q4 revenue +7% as-reported (or +21% excluding impact of large former client whose transition ended June 30, 2025); FY revenue +10% as-reported (or +20% excluding former client)
  • Gross margin expansion: nearly 200 bps full-year gross margin expansion vs 2024, attributed to care management/service delivery efficiencies and leverage with third-party partners at scale
  • Q4 CapEx: ~$5.5M, up $3.5M YoY; FY CapEx $18.4M vs $5.4M in 2024
  • Stock-based compensation: Michael Sturmer departure accelerated vesting; incremental $7.7M stock-based compensation expense in Q4 and FY2025 (not contemplated in Nov guidance); would have lifted net income/EPS vs guidance high-end absent this acceleration

AI IconCapital Funding

  • Working capital as of Dec 31: ~$350M; includes ~$310M cash/cash equivalents/marketable securities
  • No borrowings against $200M revolving credit facility and no debt of any kind
  • Share repurchases during quarter: >3.3M shares for nearly $84M; repurchased ~6.5M shares total with >$40M remaining under $200M authorization

AI IconStrategy & Ops

  • 2026 member-life outlook reduced by ~400,000 delta (admin/client-provided population updates for existing clients); management emphasized guidance relies on observed utilization/consumption rather than population counts
  • 2026 guidance utilization/consumption conservatism explicitly tied to low-end historical assumptions: Q1 utilization low-end 1.04%; ART cycles per unique utilizer assumed 0.48 (low) to 0.49 (high)
  • Select product: fixed premium structure designed for smaller fully insured employers; guardrails include no individual opt-outs and caps for high-cost claimants; Selct goes live for brokers/partners beginning 2027 (anticipates financial contribution until 2027)

AI IconMarket Outlook

  • 2026 guidance (full year): revenue $1.355B to $1.405B (+5.1% to +9%); excluding $48.5M revenue from transition-of-care client (1H 2025) implies +9.3% to +13.3%
  • 2026 profitability guidance: adjusted EBITDA $224M to $239M; net income $95.4M to $106.1M; EPS $1.19 to $1.22; adjusted EPS $1.83 to $1.95 (based on ~87M fully diluted shares)
  • 2026 stock comp: down ~35% vs 2025; stock-based comp ~6% of 2026 revenue at midpoint vs 10%+ in 2025
  • 2026 covered lives assumption: 7.2M (reduced vs prior estimate due to net reduction in lives from latest counts; management attributes to administrative type updates)
  • Q1 2026 guidance: revenue $319M to $332M (growth -1.6% to +2.5%); excluding $31.3M transition client revenue from prior-year quarter implies +9% to +13.4%
  • Q1 2026 profitability: adjusted EBITDA $51M to $55M; net income $20.8M to $23.7M; EPS $0.24 to $0.27; adjusted EPS $0.42 to $0.45

AI IconRisks & Headwinds

  • Administrative mismatches/updates: 2026 covered lives decreased (~400,000 delta) for previously existing clients; potential question of whether 2025 lives were overstated was addressed by stating guidance/model does not depend on population counts and is driven by actual utilization
  • Potential variability in ART activity/treatment pace: Q1 utilization and ART cycle assumptions set at low-end historical ranges; management noted variability could recur at low end even though unexpected variability seen in 2024 hasn’t recurred
  • Stock compensation overhang: $7.7M accelerated stock-based compensation in Q4/FY2025 created headwinds vs guidance; while 2026 reduces stock comp (~35% down), investors may watch timing
  • Progyny Rx policy uncertainty: discussion referenced a federal bill requiring 100% rebate pass-through in 2028; management expects net economics to remain similar but structure/fees could evolve (potential margin structure risk)
  • Progyny Select early-stage scale risk: predictability expected as pool grows; management indicated critical mass likely in a couple-hundred-thousand lives range (not yet at required live pool on day-one given go-live timing in 2027)

Sentiment: MIXED

Note: This summary was synthesized by AI from the PGNY Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PGNY)

© 2026 Stock Market Info — Progyny, Inc. (PGNY) Financial Profile